news
Oligonucleotide ALS therapy approved in EU
The European Commission (EC) has granted Biogen its third rare disease treatment approval in the European Union.
List view / Grid view
Ionis Pharmaceuticals
news
Otsuka to commercialise hereditary angioedema drug in Europe
Japanese company Otsuka Pharmaceutical will pay $65 million is to commercialise Ionis’ hereditary angioedema candidate in Europe.
news
Oligonucleotide synthesis market to reach $16.7 billion by 2027
Ongoing clinical trials for oligonucleotide-based therapies will propel the oligonucleotide synthesis market to reach $16.7 billion by 2027, states a new report.
news
EMA accepts marketing application for ALS treatment
The EMA has accepted the marketing authorisation application for tofersen, which could be the first treatment for a rare genetic cause of ALS.
news
Topline results show eplontersen slows disease progression in polyneuropathy patients
Data in the NEURO-TTRansform study demonstrates that eplontersen had a positive impact on disease progression, including improvement in neuropathy impairment and quality of life in a substantial number of patients.
news
AstraZeneca and Ionis to develop and commercialise eplontersen
AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals for eplontersen.
news
Alzheimer’s treatment lowers tau by nearly 50 percent in Phase I trials
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.
news
Phase III trial to study familial chylomicronemia syndrome drug initiated
Ionis Pharmaceuticals' Phase III trial to evaluate AKCEA-APOCIII-LRx in patients with familial chylomicronemia syndrome has begun.
news
First treatment for 5q spinal muscular atrophy approved by EU
1 June 2017 | By Niamh Marriott, Junior Editor
The EC has granted marketing authorisation for Ionis Pharmaceuticals’ Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA)...
news
Akcea and Ionis’ familial chylomicronaemia syndrome study a success
23 March 2017 | By Niamh Marriott, Junior Editor
Akcea Therapeutics' pivotal Phase 3 study of volanesorsen reduced triglyceride levels in patients with familial chylomicronaemia syndrome...
news
Novartis invests in Ionis’ therapies to reduce cardiovascular risk
10 January 2017 | By Niamh Marriott, Digital Editor
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
news
GSK initiates Phase 1 study of IONIS-HBV-LRx; Ionis gets milestone payment
13 January 2016 | By Victoria White
IONIS-HBV-LRx (previously referred to as ISIS-GSK6-LRx) is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus...
news
FDA grants Orphan Drug Designation to IONIS-HTTRx
5 January 2016 | By Victoria White
IONIS-HTTRx is a Gen. 2.0+ antisense drug in development for the treatment of Huntington's disease...
news
Isis Pharmaceuticals becomes Ionis Pharmaceuticals
18 December 2015 | By Victoria White
Explaining his reasoning behind the company name change, Stanley Crooke, CEO of Ionis, told Forbes: “My underlying concern was that the name was a distraction"...
